Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Company is real, not an empty shell, PR is real. thats more than most of pinks i made money on got! im long!
i agree! this is a serious deal and now people dont believe. if PR said $10Mill they probably believe. theyre all just chasing hype.
$2Mill is solid!
Technology offered by Seeker will save time and time is money.
This contract is mutually beneficial!
extended arrangement with Seeker:
Quest wish to enter into an extended arrangement with Seeker that will utilize Seeker sensor technology in Angola, which is one of the most infected landmine countries in the world. At this time, mine clearance is being undertaken manually in the traditional way and the Seeker system will be introduced and employed in suitable areas to reduce time and maximise profitability of the contracts
Im sure CEO got some more PRs, lets wait and see! should be good!
Agreed theres money to be made, especially now when things are solid!
right on Tex, sounds like you know how to get your DD done and yet you found Syncronys to be worthy of your investment. Thats how i feel too. Been here for not less than a year now!
The big picture, i believe, is to have another 4-5 contracts in 2013!! In recession times only serious and pontentially growing companies can close several million dollar contracts per year. And serious investors will DD SNTL after the contract about $2million today, no doubt!
Thanks Fritz, i trust CEO is busy and is making good progress! Wont let the investors down, in fact, just about to show us SNTL is hidden gem!
forecast net earnings in excess of $57m by the end of 2015 from the current SBUs only, as I see it on ibox and i have to agree. $57Million for sure we can count on! Now do the math folks, we will for sure see Dollar land!
4 or 5 new contracts sounds great! SNTL is undervalued if you ask me.
and revenue of $2 million is a significant amount. This company is making progress as expected.
I have been in it for a long time now, sounds solid if you ask me!
First .65, .7 , then bummm $1
$1 today is still very possible! go LTNC!
LTNC, ITs there, BIG GREEN, ON TICKER BUZZ CLOUD!
#3 Labor Smart, Inc (LTNC), BREAKOUT BOARDS
So far so good, this stock destined to see $1
Uplist and see $2-$3 right away, imo
If and company can make it during these recession times Labor Smart will!
fins looking good, chart looking good, nothing can stop LTNC, imo
.7 will see today, no doubt!
exactly, from an investment banking point of you, this company will be bought out sooner or later.
buzzz is out there! this stock is the winner of the DAY, WEEK. weee
i see $1 coming!
UPLIST is the most logical step for LTNC at this point - and they are ready!!!
Uplisting, im sure thats part of the strategy for expansion. Great entry here!!
What a nice surprise Labor Smart is truly successful!
I like what i see here nice and green.
GOOD MORNING! $PBIO!!
Groups coming into this stock! next monster multiday runner!
Agreed, Pressure BioSciences got some competitive tech. this is a winner!
Good Morning PBIO board!
buys coming in each day. 30K avarage volume is a history. will see 100k days!
go Pbio, game changer technology!
Agreed, expecting group buys anytime soon!
Again, increased chance to discover novel biomarkers -we read.
This is a game changer. Time will prove us right. $1.20 target will be met.
news:New Applications of Pressure BioSciences' PCT Platform Prominently Featured at Scientific Conference on Technologies for Prot...
Print
Alert
Pressure Biosciences, Inc. (QB) (USOTC:PBIO)
Intraday Stock Chart
Today : Tuesday 19 March 2013
Click Here for more Pressure Biosciences, Inc. (QB) Charts.
SOUTH EASTON, Mass., March 19, 2013 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that scientists from three separate research groups presented data at the recent US HUPO 9th Annual Conference indicating that sample preparation methods based on the Company's patented pressure cycling technology ("PCT") platform resulted in improved quality and/or efficiency of test results. The US HUPO conference was held March 10-13, 2013 in Baltimore, MD. The studies were conducted by scientists from ETH Zurich and the University of Zurich; from the Food and Drug Administration ("FDA") and the National Institutes of Health ("NIH"); and from the Johns Hopkins University, Louisiana State University, and Wake Forest University Schools of Medicine.
Professor Ruedi Aebersold, Professor of Molecular Systems Biology at ETH Zurich and the University of Zurich, stated that a key barrier to the development of personalized medicine cancer diagnostics and therapeutics has been the difficulty in identifying specific biomarkers. Data presented by Professor Aebersold indicated that by combining a novel biomarker strategy with a cutting-edge protein analysis method, the targeting of cellular and plasma proteins could be enhanced. This, in turn, could result in an increased chance to discover novel biomarkers. Professor Aebersold called this method "PCT-SWATH", since the use of PCT to prepare samples prior to analysis was essential to the process, offering high throughput with minimal sample loss. A case study on prostate cancer was used to illustrate the concept.
Dr. Natalia Pripuzova, from Dr. Michail Alterman's lab at the Center for Biologics Evaluation and Research of the FDA, presented data on the comparison of embryonic and IPSC stem cell lines. Cell lysis (i.e., breakage), an important part of the study's workflow, was routinely performed by Dr. Pripuzova and her colleagues using PCT in PBI's Barocycler instrument and consumables.
Dr. Zongming Fu, a member of Professor Jennifer Van Eyk's proteomics lab at the Johns Hopkins University School of Medicine, presented data on improved protein extraction and identification from archival formalin-fixed paraffin-embedded ("FFPE") human aorta samples using high heat combined with PCT. Dr. Fu and his colleagues found that high heat combined with PCT increased protein extraction yield over heat alone, resulting in a greater number of protein identifications. They concluded that this method now makes it feasible to test archives of FFPE arterial and aorta samples, including rare and difficult tissues, for biomarker discovery.
Dr. Nate Lawrence, Vice President of Sales and Marketing for PBI, commented: "We are very pleased that such highly respected protein scientists recognize the advantages of PCT in their work. First, the use of PCT to prepare stem cells for analysis opens up a new field for us, one in which we believe a focused marketing effort will result in increased PCT instrument sales in the short term. Second, we believe the data on enhanced protein recovery from FFPE samples support the continued development of our PCT-based FFPE extraction system, which we expect to release later this year, and that we expect to have a positive impact on sales in 2013 and beyond."
Dr. Lawrence continued: "Mass spectrometry-based protein analytical methods have begun to move into the personalized medicine field. These diagnostic and prognostic tools offer the potential to save many lives and greatly improve therapeutic outcomes. The PCT-SWATH method introduced by Dr. Aebersold appears to offer a superior workflow for preparing very small samples for analysis, such as routinely collected needle biopsy specimens. We believe the market for such a method is very large, fragmented, and underserved. We plan to focus greater effort in this area over the coming months, as we believe it has the potential to add significantly to sales of PCT instruments and consumables in 2013 and beyond."
news out!